Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Bamlanivimab/etesevimab for COVID-19: real-time meta analysis of 21 studies

@CovidAnalysis, July 2024, Version 38V38
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (RCT) 71% 0.29 [0.09-0.96] hosp./ER 4/101 7/52 Improvement, RR [CI] Treatment Control Gottlieb (RCT) 80% 0.20 [0.03-1.56] hosp./ER 1/37 7/52 Gottlieb (RCT) 75% 0.25 [0.03-1.92] hosp./ER 1/30 7/52 Gottlieb (RCT) 56% 0.44 [0.10-1.98] hosp./ER 2/34 7/52 Gottlieb (RCT) 92% 0.08 [0.01-0.92] hosp./ER 0/31 7/52 Alam 75% 0.25 [0.10-0.85] death 160 (n) 86 (n) Alam 65% 0.35 [0.15-1.08] hosp. 160 (n) 86 (n) Karr 40% 0.60 [0.08-4.51] hosp. 4/40 1/6 Karr 62% 0.38 [0.09-1.52] hosp./ER 5/40 2/6 Corwin 80% 0.20 [0.03-1.42] death 1/780 35/5,337 Corwin 39% 0.61 [0.45-0.79] hosp. 57/780 490/5,337 Webb 80% 0.20 [0.03-1.46] death 1/479 57/5,536 Webb 53% 0.47 [0.31-0.72] hosp. 22/479 538/5,536 Webb 27% 0.73 [0.65-0.82] hosp./ER 65/479 1,018/5,536 Dougan (DB RCT) 95% 0.05 [0.00-0.90] death 0/518 9/517 Dougan (DB RCT) 70% 0.30 [0.16-0.59] death/hosp. 11/518 36/517 Dougan (DB RCT) 11% 0.89 [0.82-0.97] recov. time 518 (n) 517 (n) Dougan (DB RCT) 67% 0.33 [0.25-0.45] viral+ 50/508 147/499 Cooper -7% 1.07 [0.55-2.07] death 12/2,900 33/8,534 Cooper 45% 0.55 [0.07-3.99] death 1/473 33/8,534 Cooper -17% 1.17 [0.59-2.32] death 11/2,427 33/8,534 Cooper 17% 0.83 [0.53-1.30] ICU 24/2,900 85/8,534 Cooper 58% 0.42 [0.10-1.72] ICU 2/473 85/8,534 Cooper 9% 0.91 [0.57-1.45] ICU 22/2,427 85/8,534 Cooper 24% 0.76 [0.65-0.89] hosp. 181/2,900 703/8,534 Cooper 5% 0.95 [0.69-1.30] hosp. 37/473 703/8,534 Cooper 28% 0.72 [0.61-0.86] hosp. 144/2,427 703/8,534 Rubin 44% 0.56 [0.07-4.33] death 1/191 10/1,066 Rubin 65% 0.35 [0.12-0.94] hosp. 16/191 121/1,065 Leavitt 30% 0.70 [0.26-1.92] hosp. 6/136 9/143 Leavitt 42% 0.58 [0.36-0.96] misc. 20/136 36/143 Delasobera -119% 2.19 [0.23-20.9] death 3/253 1/185 Delasobera 52% 0.48 [0.27-0.85] hosp. 17/253 26/185 Delasobera 20% 0.80 [0.46-1.40] progression 23/253 21/185 Dale 89% 0.11 [0.02-0.55] death 5/56 9/19 Dale 86% 0.14 [0.04-0.52] progression 6/56 10/19 Dale 54% 0.46 [0.08-1.97] progression 6/56 3/19 BLAZE-4 Dougan (RCT) -51% 1.51 [0.26-8.90] hosp. 3/127 2/128 CT​1 BLAZE-4 Dougan (RCT) 9% 0.91 [0.88-0.93] viral load 125 (n) 128 (n) CT​1 BLAZE-4 Dougan (RCT) 24% 0.76 [0.70-0.82] viral load 125 (n) 128 (n) CT​1 BLAZE-4 Dougan (RCT) 12% 0.88 [0.84-0.91] viral load 125 (n) 128 (n) CT​1 BLAZE-4 Dougan (RCT) 35% 0.65 [0.36-1.15] viral+ 16/127 25/128 CT​1 Wilden 51% 0.49 [0.23-1.04] hosp. n/a n/a Fivelstad -144% 2.44 [0.10-59.6] death 1/335 0/148 Fivelstad 63% 0.37 [0.21-0.64] hosp. 21/335 25/148 Kip 15% 0.85 [0.51-1.41] death/hosp. 20/349 47/695 Kip 31% 0.69 [0.41-1.18] death/hosp. 17/221 49/442 ACTIV-3 ACTIV-3/TIC.. (RCT) -100% 2.00 [0.69-5.83] death 9/163 5/151 Bariola 67% 0.33 [0.10-1.01] death 4/234 12/234 Bariola 64% 0.36 [0.20-0.61] death/hosp. 16/234 45/234 Bariola 61% 0.39 [0.22-0.70] hosp. 15/234 39/234 Ganesh 74% 0.26 [0.05-1.20] death 2/1,789 8/1,832 Ganesh 49% 0.51 [0.24-1.09] ICU 10/1,789 20/1,832 Ganesh 37% 0.63 [0.43-0.91] hosp. 44/1,789 72/1,832 Priest (PSM) 0% 1.00 [0.33-3.07] death 6/379 6/379 Priest (PSM) -4% 1.04 [0.78-1.38] hosp. 79/379 76/379 Priest (PSM) -5% 1.05 [0.73-1.52] hosp./ER 379 (n) 379 (n) ACTIV-2/A5401 Chew (RCT) 25% 0.75 [0.26-2.10] hosp. 6/159 8/158 ACTIV-2/A5401 Chew (RCT) 52% 0.48 [0.09-2.49] hosp. 2/48 4/46 ACTIV-2/A5401 Chew (RCT) -1% 1.01 [0.26-3.93] hosp. 4/111 4/112 ACTIV-2/A5401 Chew (RCT) -14% 1.14 [0.00-455] recov. time 48 (n) 46 (n) ACTIV-2/A5401 Chew (RCT) -17% 1.17 [0.98-1.40] recov. time 111 (n) 112 (n) ACTIV-2/A5401 Chew (RCT) -1% 1.01 [0.86-1.17] progression 42/48 40/46 ACTIV-2/A5401 Chew (RCT) 2% 0.98 [0.91-1.05] progression 102/111 105/112 ACTIV-2/A5401 Chew (RCT) 26% 0.74 [0.62-0.90] viral load 48 (n) 46 (n) ACTIV-2/A5401 Chew (RCT) 35% 0.65 [0.40-1.04] viral load 111 (n) 112 (n) Lilly (RCT) 57% 0.43 [0.28-0.67] symp. case 483 (n) 482 (n) Lilly (RCT) 80% 0.20 [0.08-0.47] symp. case 150 (n) 149 (n) Bamlanivimab/etesevimab COVID-19 outcomes c19early.org July 2024 1 CT: study uses combined treatment Favors bamlanivimab/e.. Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit